De Novo Design of Self-Assembling Foldamers That Inhibit Heparin–Protein Interactions

A series of self-associating foldamers have been designed as heparin reversal agents, as antidotes to prevent bleeding due to this potent antithrombotic agent. The foldamers have a repeating sequence of Lys-Sal, in which Sal is 5-amino-2-methoxy-benzoic acid. These foldamers are designed to self-associate along one face of an extended chain in a β-sheet-like interaction. The methoxy groups were included to form intramolecular hydrogen bonds that preclude the formation of very large amyloid-like aggregates, while the positively charged Lys side chains were introduced to interact electrostatically with the highly anionic heparin polymer. The prototype compound (Lys-Sal)4 carboxamide weakly associates in aqueous solution at physiological salt concentration in a monomer-dimer-hexamer equilibrium. The association is greatly enhanced at either high ionic strength or in the presence of a heparin derivative, which is bound tightly. Variants of this foldamer are active in an antithrombin III–factor Xa assay, showing their potential as heparin reversal agents.

[1]  D. Eisenberg,et al.  Amyloid β-Sheet Mimics that Antagonize Amyloid Aggregation and Reduce Amyloid Toxicity , 2012, Nature Chemistry.

[2]  S. Gellman,et al.  Structural consequences of beta-amino acid preorganization in a self-assembling alpha/beta-peptide: fundamental studies of foldameric helix bundles. , 2010, Journal of the American Chemical Society.

[3]  S. Gellman,et al.  An alpha/beta-peptide helix bundle with a pure beta3-amino acid core and a distinctive quaternary structure. , 2009, Journal of the American Chemical Society.

[4]  Erinna F. Lee,et al.  High-resolution structural characterization of a helical alpha/beta-peptide foldamer bound to the anti-apoptotic protein Bcl-xL. , 2009, Angewandte Chemie.

[5]  W. DeGrado,et al.  De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers , 2009, Proceedings of the National Academy of Sciences.

[6]  Andrew K. Udit,et al.  Heparin Antagonism by Polyvalent Display of Cationic Motifs on Virus‐Like Particles , 2009, Chembiochem : a European journal of chemical biology.

[7]  J. Nowick.  Exploring beta-sheet structure and interactions with chemical model systems. , 2008, Accounts of chemical research.

[8]  A. Schepartz,et al.  Toward beta-amino acid proteins: design, synthesis, and characterization of a fifteen kilodalton beta-peptide tetramer. , 2008, Journal of the American Chemical Society.

[9]  Scott J. Shandler,et al.  Foldamers as versatile frameworks for the design and evolution of function. , 2007, Nature chemical biology.

[10]  Alanna Schepartz,et al.  High-Resolution Structure of a β-Peptide Bundle , 2007 .

[11]  R. La Spina,et al.  Polycationic calix[8]arenes able to recognize and neutralize heparin. , 2006, Organic & biomolecular chemistry.

[12]  J. Leger,et al.  Interstrand interactions between side chains in a double-helical foldamer. , 2006, Angewandte Chemie.

[13]  M. Klein,et al.  The design and evaluation of heparin-binding foldamers. , 2005, Angewandte Chemie.

[14]  I. Huc,et al.  Intramolecular Versus Intermolecular Induction of Helical Handedness in Pyridinedicarboxamide Oligomers , 2005 .

[15]  Joshua A. Kritzer,et al.  Solution Structure of a β-Peptide Ligand for hDM2 , 2005 .

[16]  Bing Gong,et al.  Well-defined secondary structures. , 2004, European journal of biochemistry.

[17]  I. Huc.  Aromatic Oligoamide Foldamers , 2004 .

[18]  R. J. Doerksen,et al.  Nontoxic membrane-active antimicrobial arylamide oligomers. , 2004, Angewandte Chemie.

[19]  J. Huntington,et al.  Crystal structure of antithrombin in a heparin-bound intermediate state. , 2003, Biochemistry.

[20]  S. Olson,et al.  Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. , 2002, Trends in cardiovascular medicine.

[21]  S. Olson,et al.  Specificity of the basic side chains of Lys114, Lys125, and Arg129 of antithrombin in heparin binding. , 2002, Biochemistry.

[22]  B. Gong,et al.  A noncovalent approach to antiparallel β-sheet formation , 2002 .

[23]  R. Linhardt,et al.  Heparin-protein interactions. , 2002, Angewandte Chemie.

[24]  C. Page,et al.  Novel drug development opportunities for heparin , 2002, Nature Reviews Drug Discovery.

[25]  Matthew J. Mio,et al.  A field guide to foldamers. , 2001, Chemical reviews.

[26]  M. Maurin,et al.  Physical chemical stability of warfarin sodium , 2001, AAPS PharmSci.

[27]  B. Gong,et al.  A Highly Stable, Six-Hydrogen-Bonded Molecular Duplex , 2000 .

[28]  Harold L. Ickes,et al.  A NEW APPROACH FOR THE DESIGN OF SUPRAMOLECULAR RECOGNITION UNITS : HYDROGEN-BONDED MOLECULAR DUPLEXES , 1999 .

[29]  Samuel H. Gellman,et al.  Foldamers: A Manifesto , 1998 .

[30]  J. Abrahams,et al.  The anticoagulant activation of antithrombin by heparin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Weiler,et al.  Pattern and spacing of basic amino acids in heparin binding sites. , 1997, Archives of biochemistry and biophysics.

[32]  J. Weiler,et al.  Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. , 1995, Archives of biochemistry and biophysics.

[33]  H. Margalit,et al.  Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. , 1993, The Journal of biological chemistry.

[34]  A. Cardin,et al.  Molecular Modeling of Protein‐Glycosaminoglycan Interactions , 1989, Arteriosclerosis.

[35]  G. Jones,et al.  A comparison of the strength of binding of antithrombin III, protamine and poly(L-lysine) to heparin samples of different anticoagulant activities. , 1986, Biochimica et biophysica acta.

[36]  K. Nordling,et al.  Extension and structural variability of the antithrombin-binding sequence in heparin. , 1984, The Journal of biological chemistry.

[37]  M. Petitou,et al.  Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. , 1983, Biochemical and biophysical research communications.

[38]  U. Lindahl,et al.  Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Linker,et al.  Structure of the antithrombin-binding site in heparin. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Rosenberg,et al.  The purification and mechanism of action of human antithrombin-heparin cofactor. , 1973, The Journal of biological chemistry.

[41]  B. Dani,et al.  Skeletal effects of parathyroid hormone (1–34) in ovariectomized rats with or without concurrent administration of salmon calcitonin , 2008, AAPS PharmSci.

[42]  U Lindahl,et al.  Further characterization of the antithrombin-binding sequence in heparin. , 1982, Carbohydrate research.